Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 2, 2013, Pages 211-218

  Hogg, Ronald J ^a   Friedman, Aaron ^a   Greene, Tom ^a   Radeva, Milena ^a   Budisavljevic, Milos N ^a   Gassman, Jennifer ^a   Gipson, Debbie S ^a   Ashley Jefferson, J ^a   John, Eunice G ^a   Kaskel, Frederick J ^a   Moudgil, Asha ^a   Moxey Mims, Marva ^a   Ortiz, Luis A ^a   Schelling, Jeffrey R ^a   Schnaper, William ^a   Srivastava, Tarak ^a   Trachtman, Howard ^a   Matti Vehaskari, V ^a   Wong, Craig ^a   Woronieki, Robert P ^a   Van Why, Scott K ^a   Zolotnitskaya, Anna ^a   more..

^a Scott and White Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; LISINOPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; URINALYSIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PROTEINURIA; YOUNG ADULT;

EID: 84875038359     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08330812     Document Type: Article

References (18)

1. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM: Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25: 534-542, 1995
2. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061-1068, 2005
3. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, Gibson K, Thomas DB: Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 21: 344-349, 2006
4. Burgess E: Management of focal segmental glomerulosclerosis: Evidence-based recommendations. Kidney Int Suppl 70: S26-S32, 1999
5. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Della Casa-Alberighi O: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43: 1377-1384, 1993
6. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, MaxwellDR, Kunis CL; North AmericaNephrotic Syndrome Study Group: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 56: 2220-2226, 1999
7. Heering P, Braun N, Müllejans R, Ivens K, Zäuner I, Fünfstück R, Keller F, Krämer BK, Schollmeyer P, Risler T, Grabensee B; German Collaborative Glomerulonephritis Study Group: Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 43: 10-18, 2004
8. Lieberman KV, Tejani A: A randomized double-blind placebocontrolled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7: 56-63, 1996
9. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D'Agati VD, Friedman AL: Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80: 868-878, 2011
10. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL: Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int 79: 678-685, 2011
11. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263, 1976
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
13. Deegens JK, Wetzels JF: Immunosuppressive treatment of focal segmental glomerulosclerosis: Lessons from a randomized controlled trial. Kidney Int 80: 798-801, 2011
14. Kangovi S, Edwards M, Woloszynek S, Mitra N, Feldman H, Kaplan BS, Meyers KE: Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis. Pediatr Nephrol 27: 813-819, 2012
15. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D: Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 17: 2011-2013, 2002
16. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W: Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 62: 405-411, 2004
17. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, Sakhuja V, Jha V: Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol Dial Transplant 23: 1926-1930, 2008
18. de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SPL, de Andrade OV, Guidoni EBM, Scheffer DK, Martini Filho D, Toporovski J, Benini V: Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 25: 453-460, 2010